Oxford BioTherapeutics Ltd., of Oxford, UK, and BioWa Inc., of Princeton, N.J., entered into a license agreement to provide OBT with access to BioWa's patented Potelligent Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies

GW Pharmaceuticals plc, of Porton Down, UK, reported it entered an exclusive license agreement with Novartis Pharma AG, of Basel, Switzerland, to commercialize Sativex, which is being developed as a treatment for spasticity due to multiple sclerosis, in Australia, New Zealand, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel/Palestine) and Africa

BioWa Inc., of Princeton, N.J., and Oxford BioTherapeutics Ltd., of Oxford, UK, entered into a license agreement to provide OBT with access to BioWa's patented Potelligent Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies...The suit also alleges that Watson violated settlement and license agreements signed in November 2007, arising from an ANDA that Watson filed in 2006 that also sought approval to market generic versions of Adderall XR

Cellectis SA, of Paris, signed a license agreement with an undisclosed pharmaceutical firm covering certain uses of its homologous recombination technology in the oncology space

Cellectis SA, of Paris, signed a license agreement with an undisclosed pharmaceutical firm covering certain uses of its homologous recombination technology in the oncology space

Morphotek Inc., of Exton Pa., signed a collaboration and license agreement with Biocare Medical LLC, of Concord, Calif., to develop and commercialize an immunohistochemical diagnostic kit based on Morphotek's monoclonal antibody for human folate receptor alpha

Sucampo Manufacturing and Research AG, a wholly-owned subsidiary of Sucampo Pharmaceuticals Inc., of Bethesda, Md., entered a license agreement with R-Tech Ueno Ltd, of Tokyo, Japan, for Rescula (unoprostone isopropyl) eye drops

The collaboration includes an option to Apeiron to enter a worldwide, exclusive license agreement with the clinic relating to the compounds, and an Apeiron-sponsored research agreement with the clinic relating to those compounds and approach, the company said

The collaboration includes an option to Apeiron to enter a worldwide, exclusive license agreement with the clinic relating to the compounds, and an Apeiron-sponsored research agreement with the clinic relating to those compounds and approach, the company said

Proteonomix Inc., of Mountainside, N.J., entered an exclusive license agreement with an unnamed partner to develop technology for the mobilization of bone marrow stem cells

In other news, Elan and Celgene Corp., of Summit, N.J., entered a settlement and license agreement resolving a patent infringement suit involving breast cancer treatment Abraxane

plc, of Dublin, Ireland, and Celgene Corp., of Summit, N.J., entered a settlement and license agreement resolving a patent infringement suit involving breast cancer treatment Abraxane

The OncoMed agreement was related to the antibody OMP-59R5, which has begun a Phase I trial in patients with advanced solid tumors under a 2006 license agreement between the two companies

The OncoMed agreement was related to the antibody OMP-59R5, which has begun a Phase I trial in patients with advanced solid tumors under a 2006 license agreement between the two companies

The license agreement has an expanded scope for thermostable vaccines for biodefense

Radient Pharmaceuticals Corp., of Tustin, Calif., said its wholly owned subsidiary, NuVax Therapeutics Inc., signed an exclusive license agreement with the University of Florida College of Medicine in Gainesville, Fla., for the use and commercialization of four immune-gene therapy tools and systems developed at the university

In other news, Cellectis signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage, an approach for the targeted modification of genomes...Prolor had previously developed a long-acting oxyntomodulin peptide for obesity under a limited, option-to-license agreement from Yeda and has now exercised its option

Cellectis SA, of Paris, has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage, an approach for the targeted modification of genomes...Repligen Corp., of Waltham, Mass., entered an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment

Depomed entered into the DM-1796 license agreement with Solvay Pharmaceuticals in November 2008...Abbott Products assumed the license agreement as a result of the acquisition of Solvay's pharmaceutical business by Abbott